Wonbiogen Co.,Ltd.

307280KOSDAQPharmaceuticals

Wonbiogen Co.,Ltd. (307280, KOSDAQ) reported KRW 35bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
2021182-13827Consolidated
202227533927Consolidated
202330764333Consolidated
202430654137Consolidated
202535864843Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
202111.5%-3.7%69.8%-2.5%
202219.3%12.2%68.9%12.2%
202324.1%20.1%76%18.3%
202421%17.5%90.3%14.3%
202522.5%18.3%89.5%15.2%

Revenue moved 98.9% between 2021 and 2025.

Net profit was positive in the 4 most recent consecutive years on file. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 43bn
Close priceKRW 6,030
Listed shares7,094,627
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Who runs it

Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.

NameTitleBoard seatYears in post
Kim Won-il (김원일)Representative Director (CEO)Inside director19 years

Roman spellings are ours, converted from the Korean filing. The person may spell their own name differently in English. The Korean name in brackets is what was filed.

Workforce — a side measure, not the main one

Employees (2025)77
Women32 (41.6%)
Average tenure4 years
Annual pay, menKRW 65,572
Annual pay, womenKRW 45,501
Pay ratio, women to men69.4%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →